心肾综合征病理生理学机制及临床治疗进展  

Advance in pathophysiology and treatment of cardiorenal syndrome

作　　者：严铭玉[1] 王骏[1] 王鸣和[1] 

机构地区：[1]上海市静安区中心医院心内科,上海200040

出　　处：《世界临床药物》2010年第10期625-630,共6页World Clinical Drug

摘　　要：心肾综合征(CRS)以心肾衰竭、肾功能恶化及利尿剂抵抗为临床特征性表现,但其发病机制至今尚未阐明。本文聚焦肾灌注压降低、神经激素过度激活、一氧化氮(NO)与活性氧族(ROS)之间的失衡,以及管-球反馈异常等,综述近年血管加压素受体拮抗剂及选择性腺苷A1受体拮抗剂等新制剂的临床治疗策略。The clinical features of cardiorenal syndrome（CRS） are cardiorenal failure, renal function deterioration and diuretics resistance. However, its pathogenesis is still unclear. This review focuses on the reduction of renal perfusion pressure, excessive activation of neurohormone, imbalance of NO and ROS, and abnormality of tubulo-glomenular feedback. The clinical applications of vasopressin receptor antagonists and selective A1 adenosine receptor antagonists are also discussed in this review.

关 键 词：心肾综合征 病理生理学 机制 治疗 

分 类 号：R541.6[医药卫生—心血管疾病] R972.4[医药卫生—内科学]